ArticleCommunications biology2026
Integrative structural analysis of the human LRP2-LRPAP1 complex reveals multiple regulatory sites.
Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The low-density lipoprotein receptor-related protein 2 (LRP2) is an endocytic receptor implicated in the homeostasis of multiple organs. While the low-density lipoprotein receptor-related protein-associated protein 1 (LRPAP1) interacts with LRP2, its regulatory role remains elusive. Past studies showed that a single LRPAP1 molecule binds to LRP2 via complement-type repeats. However, many domains of this kind appear unoccupied in LRP2 within the complex. Here, we investigate if multiple LRPAP1 copies could bind the receptor. Using an integrative structural approach, we characterise the human recombinant LRP2 extracellular domain and its complex with LRPAP1, by identifying three additional LRPAP1 binding sites. Notably, two of these sites overlap with ligand-binding regions, suggesting that LRPAP1 may regulate LRP2 ligand-binding activity. Furthermore, we highlight LRPAP1-LRP2 interaction sites unique within the receptor's family and pathogenic LRP2 mutations located at LRP2-LRPAP1 interfaces. Overall, our study redefines the landscape of the LRP2-LRPAP1 interaction, providing insights into its clinical and functional role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.